Valuation: Valneva SE

Market Cap 441M 494M 408M 369M 691M 46.89B 702M 4.9B 1.94B 24.57B 1.85B 1.81B 77.46B P/E 2026 *
-5.34x
P/E 2027 * 8.42x
Enterprise Value 575M 644M 531M 481M 900M 61.11B 915M 6.39B 2.53B 32.02B 2.42B 2.36B 101B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 1.78x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day-1.87%
1 week-6.24%
Current month-14.96%
1 month-15.43%
3 months+10.04%
6 months-4.36%
Current year-40.36%
1 week 5.25
Extreme 5.25
5.84
1 month 5.25
Extreme 5.25
6.49
Current year 4.75
Extreme 4.75
12.18
1 year 4.75
Extreme 4.75
12.18
3 years 3.62
Extreme 3.62
14.49
5 years 3.62
Extreme 3.62
67.84
10 years 3.62
Extreme 3.62
67.84
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.87%-6.24% - - 494M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.06%+2.41%+48.08%+140.89% 42.57B
Weighted average by Cap. +0.39%+2.73%+46.02%+142.84%

Financials

2026 *2027 *
Net sales 151M 169M 139M 126M 237M 16.05B 240M 1.68B 665M 8.41B 635M 621M 26.52B 283M 317M 262M 237M 444M 30.12B 451M 3.15B 1.25B 15.78B 1.19B 1.17B 49.76B
Net income -81.11M -90.83M -74.93M -67.91M -127M -8.62B -129M -902M -357M -4.52B -341M -334M -14.24B 53.07M 59.43M 49.03M 44.43M 83.12M 5.64B 84.5M 590M 234M 2.96B 223M 218M 9.32B
Net Debt 134M 150M 124M 112M 209M 14.21B 213M 1.49B 589M 7.45B 562M 550M 23.48B 62.48M 69.96M 57.72M 52.3M 97.85M 6.64B 99.47M 695M 275M 3.48B 263M 257M 10.97B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
23/10/26 $5.260 -1.87% 6,408
22/10/26 $5.360 -3.60% 22,616
21/10/26 $5.560 -2.28% 137,263
20/10/26 $5.690 +3.27% 13,100
19/10/26 $5.510 -1.78% 9,143
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.326EUR
Average target price
6.193EUR
Spread / Average Target
+166.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE